Demystify Meds for Moderate to Severe Crohn’s Disease
August 2023
We’re getting questions about how to manage moderate to severe Crohn’s disease...due to a new indication for upadacitinib (Rinvoq).
Continue to use shared-decision making and lean toward a “top-down” approach...with earlier use of biologics before steroid dependence or disease progression. And work closely with GI colleagues.
Biologics include TNF-alpha blockers (adalimumab, etc)...anti-interleukin meds (ustekinumab, etc)...and selective adhesion blockers (vedolizumab, etc).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote